Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate Cancer

Intermediate Risk Prostate Cancer Clinical Trial

Official title: "Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate Cancer" "Hypofraktionierte Protonentherapie Mit Spot-Scanning-Technik Bei Prostatakarzinom Mit Niedrigem Oder Mittlerem Risiko"

Status Recruiting

Clinical Trial Summary

This prospective study assess the effectiveness and safety of hypofractionated proton radiotherapy in the treatment of intermediate and low risk prostate cancer.

Clinical Trial Description

The purpose of this study is to assess the effectiveness and safety of spot-scanning based hypofractionated proton radiotherapy for the treatment of intermediate and low risk prostate cancer. The treatment effectiveness is defined as freedom from biochemical failure. Treatment safety will be documented with acute and late morbidity assessments. Dose volume relationships for late side effects in organs at risk surrounding the prostate will be calculated from the dose volume histogram parameters assessed during treatment planning. Patient assessed Quality of life data including sexual function will be collected to increase our understanding how the reduction of normal tissue irradiation with proton therapy with subsequent decrease in functional impairments will overall affect the patient's life. ;

Related Conditions & MeSH terms

• Intermediate Risk Prostate Cancer
• Low Risk Prostate Cancer
• Prostatic Neoplasms

• NCT number: NCT03740191
• Study type: Interventional
• Source: EBG MedAustron GmbH
• Contact: Carola Lütgendorf-Caucig, MD MPH MBA
• Phone: +43 2622 26 100
• Email: carola.luetgendorf-caucig@medaustron.at
• Status: Recruiting
• Phase: N/A
• Start date: July 3, 2018
• Completion date: December 2027